Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488886 | 0.95 | LTA4H (0.42) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL15426891 | 0.93 | SOAT1 (0.41) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL16888352 | 0.93 | SOAT1 (0.41) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18724647 | 0.93 | SOAT1 (0.41) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL13284463 | 0.93 | SOAT1 (0.41) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| Butylamine SCHEMBL20954570 | 0.92 | SMN1; SMN2 (0.38) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6276817 | 0.92 | SOAT1 (0.40) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| Tetrabuthylammonium SCHEMBL27537076 | 0.89 | SMYD2 (0.36) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL706843 | 0.89 | SMYD2 (0.40) | LTA4HSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL20954569 | 0.86 | SIGMAR1 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | claimed |
| WO-2025035202-A1 | IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| US-20160052981-A1 | REGULATORS OF NFAT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| WO-2014170642-A2 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| EP-2651933-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Janssen R&D Ireland (IE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080449-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
| US-8163950-B2 | Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7659357-B2 | Precursor organosilicon polymer of 1,2-Bis(dimethylethoxysilyl)ethane, 1,4-bis(dimethylethoxysilyl)benzene, tetraethoxysilane, methyltriethoxysilane, phenyltriethoxysilane; dielectric (DE) films having etching/chemical/moisture resistance; adhesion; low DE constant; minimal wiring delay; high speed | FUJITSU LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090082585-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | BANNOU TADASHI | 2009-03-26 | — | — | US | disclosed |
| US-7459577-B2 | Reacting a chlorosilane with grignard reagent | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20070026689-A1 | Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same | FUJITSU LIMITED (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20050070730-A1 | Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1023333-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| CN-1228082-A | Synthesis of bisindolylmalimides | LILLY CO ELI (US) | 1999-09-08 | — | — | CN | disclosed |
| WO-1999012979-A1 | PROCESSES FOR IMPROVING STABILITY OF LIVING POLYMERIZATION CHAIN ENDS | FMC CORPORATION (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | LTA4H 4239/4885SMYD2 3212/4885CYP3A4 2501/4885 |
| US-20090082585-A1 | PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES | MLX, HAX1, RPS4X | LTA4H 1128/4885SMYD2 963/4885CYP3A4 435/4885 |
| US-20050070730-A1 | Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes | MLX, HAX1, GRIA3 | LTA4H 1556/4885SMYD2 1394/4885CYP3A4 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.